bispecific ADCs and other formats. The company is progressing its ADC pipeline and BiTAC (bi-targeted tumour-associated cytotoxicity) formats towards clinical development, leveraging ...

As a bispecific ADC, JS212 has a key advantage over traditional ADCs that only target one protein: it can attack tumors via either EGFR or HER3, potentially increasing its effectiveness against a ...

CS5007 (EGFR/HER3 bispecific ADC): CS5007 is a bispecific ADC targeting both EGFR and HER3, developed with CStone's proprietary ADC platform. It is composed of EGFR/HER3 bispecific antibody ...

As a bispecific ADC, JS212 has a key advantage over traditional ADCs that only target one protein: it can attack tumors via either EGFR or HER3, potentially increasing its effectiveness against a ...

Veraxa Biotech has entered a joint discovery partnership with OmniAb tp develop a bispecific antibody drug conjugate (bsADC) ...

Alphamab has developed JSKN021, a dual payload bispecific ADC targeting EGFR/HER3, utilizing glycan-specific conjugation technology. The novel DNA topoisomerase I inhibitor T01 and the microtubule ...

IBI3014 is a bispecific ADC targeting TROP2 and PD-L1. Its dual mechanism integrates TROP2-directed tumor killing with PD-L1 immune checkpoint blockade, enhancing immunogenic cell death and T cell ...

SAN FRANCISCO and SUZHOU, China, April 27, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that ...